Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Avastin
Avastin
Roche gets European approval for Tecentriq combo vs. lung cancer
Reuters
Fri, 03/8/19 - 10:12 am
Roche
Europe
Tecentriq
Avastin
lung cancer
metastatic non-squamous non-small cell lung cancer
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
Tue, 03/5/19 - 09:40 am
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Genentech Scores FDA Approval for Tecentriq and Avastin Combo in NSCLC
BioSpace
Fri, 12/7/18 - 11:59 am
Genentech
FDA
Tecentriq
Avastin
non-squamous cell non-small cell lung cancer
One more shot at slowing Keytruda’s first-line lung cancer domination
EP Vantage
Wed, 11/28/18 - 10:12 am
Keytruda
Merck
Roche
Tecentriq
Avastin
lung cancer
Novartis, Bayer consider appeal as court says Avastin can be used in AMD
Pharmaforum
Mon, 09/24/18 - 03:37 pm
UK
Roche
Avastin
wet age-related macular degeneration
Novartis
Bayer
In a rare delay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecentriq/Avastin triple for lung cancer
Endpoints
Thu, 09/6/18 - 11:42 am
Genentech
Roch
Tecentriq
Avastin
lung cancer
FDA
Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week
Fierce Pharma
Mon, 03/26/18 - 10:37 pm
Roche
Avastin
Tecentriq
lung cancer
AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
S&P Global
Wed, 03/14/18 - 09:38 pm
AbbVie
Roche
Humira
Rituxan
Herceptin
Avastin
Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down
Endpoints
Thu, 03/8/18 - 09:39 am
clinical trials
VBL Therapeutics
VB-111
Roche
Avastin
glioblastoma
Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals
Fierce Pharma
Tue, 01/16/18 - 06:56 pm
Roche
Pharma CEOs
Severin Schwan
biosimilars
Herceptin
Rituxan
Avastin
The 2018 biosimilar litigation landscape: A primer
BioPharma Dive
Sun, 12/17/17 - 11:35 am
biosimilars
FDA
Neupogen
Neulasta
Remicade
Epogen
Enbreal
Humira
Avastin
Herceptin
Roche's Fight With Pfizer May Be Just The Beginning
Forbes
Mon, 12/11/17 - 11:31 pm
Roche
Pfizer
Herceptin
biosimilars
cancer
Avastin
Rituxan
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Yahoo/Reuters
Fri, 12/8/17 - 10:00 am
Roche
Novartis
Italy
Avastin
Lucentis
marketing manipulation
FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy
Bloomberg
Mon, 09/18/17 - 09:41 am
FDA
Avastin
biosimilars
Roche
FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin
Endpoints
Fri, 09/15/17 - 09:14 am
FDA
Scott Gottlieb
Amgen
Allergan
biosimilars
Mvasi
Roche
Avastin
Key FDA Regulatory Events to Watch Out for in Sep 2017
Yahoo/Zacks.com
Mon, 09/4/17 - 10:31 pm
FDA
Mylan Labs
Herceptin
biosimilars
trastuzumab
Shingrix
GSK
Pfizer
Sutent
PTC Therapeutics
Translarna
Amgen
Allergan
Avastin
Poor test results for Roche cloud growth prospects
Yahoo/Reuters
Wed, 07/19/17 - 09:54 am
Roche
biosimilars
Rituxan
Herceptin
Avastin
The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise
Endpoints
Wed, 07/12/17 - 10:36 am
Roche
biosimilars
Avastin
Herceptin
ABP 215
Amgen
MYL-14010
Mylan Labs
Rituxan
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
Fri, 06/30/17 - 11:06 am
prescription data
Sanofi
Lantus
Roche
Herceptin
Avastin
Celgene
Revlimid
JNJ
Merck
Remicade
Biogen
Rituxan
Amgen
Enbrel
Gilead Sciences
Harvoni
AbbVie
Humira
Amid sales growth, Roche plans defense from biosimilar threats
BioPharma Dive
Fri, 04/28/17 - 10:30 am
Roche
biosimilars
Rituxan
Herceptin
Avastin
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »